Hybio Pharmaceutical Net Asset Quality Index
Hybio Pharmaceutical net asset quality index. Hybio Pharmaceutical (300199) has a Net Asset Quality Index of 21.0% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.17 Billion minus total liabilities of CN¥2.50 Billion yields net assets of CN¥666.08 Million. A higher index indicates a stronger, lower-leverage balance sheet. Check Hybio Pharmaceutical (300199) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Hybio Pharmaceutical (2007–2024)
Net asset quality index of Hybio Pharmaceutical from 2007 to 2024. This chart shows how Hybio Pharmaceutical's Net Asset Quality Index has evolved across 18 annual periods from 2007 to 2024. As of September 2025, the index stands at 21.0%, representing net assets of CN¥666.08 Million against total assets of CN¥3.17 Billion CNY. See 300199 book value for net asset value and shareholders' equity analysis.
Hybio Pharmaceutical Net Asset Quality Index by Year (2007–2024)
Hybio Pharmaceutical net asset quality index by year from 2007 to 2024. The table below presents the year-by-year Net Asset Quality Index for Hybio Pharmaceutical from 2007 to 2024, covering 18 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 300199 stock market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 19.8% | CN¥597.05 Million | CN¥3.01 Billion | CN¥2.41 Billion | ▼ -4.1 pp |
| 2023 | 23.9% | CN¥783.21 Million | CN¥3.28 Billion | CN¥2.49 Billion | ▼ -12.0 pp |
| 2022 | 35.9% | CN¥1.30 Billion | CN¥3.61 Billion | CN¥2.31 Billion | ▼ -6.3 pp |
| 2021 | 42.2% | CN¥1.65 Billion | CN¥3.91 Billion | CN¥2.26 Billion | ▲ +0.5 pp |
| 2020 | 41.7% | CN¥1.68 Billion | CN¥4.02 Billion | CN¥2.34 Billion | ▼ -5.5 pp |
| 2019 | 47.3% | CN¥2.23 Billion | CN¥4.72 Billion | CN¥2.49 Billion | ▼ -12.7 pp |
| 2018 | 59.9% | CN¥3.39 Billion | CN¥5.66 Billion | CN¥2.27 Billion | ▼ -13.4 pp |
| 2017 | 73.3% | CN¥3.88 Billion | CN¥5.30 Billion | CN¥1.41 Billion | ▼ -7.5 pp |
| 2016 | 80.9% | CN¥3.60 Billion | CN¥4.46 Billion | CN¥852.42 Million | ▲ +6.5 pp |
| 2015 | 74.4% | CN¥2.64 Billion | CN¥3.55 Billion | CN¥908.68 Million | ▼ -2.0 pp |
| 2014 | 76.4% | CN¥1.30 Billion | CN¥1.70 Billion | CN¥401.32 Million | ▼ -10.9 pp |
| 2013 | 87.2% | CN¥1.12 Billion | CN¥1.29 Billion | CN¥164.48 Million | ▼ -3.2 pp |
| 2012 | 90.4% | CN¥1.02 Billion | CN¥1.12 Billion | CN¥107.42 Million | ▼ -3.8 pp |
| 2011 | 94.2% | CN¥976.09 Million | CN¥1.04 Billion | CN¥59.56 Million | ▲ +9.4 pp |
| 2010 | 84.8% | CN¥180.59 Million | CN¥212.89 Million | CN¥32.30 Million | ▲ +14.8 pp |
| 2009 | 70.0% | CN¥127.74 Million | CN¥182.47 Million | CN¥54.73 Million | ▼ -2.7 pp |
| 2008 | 72.7% | CN¥99.23 Million | CN¥136.55 Million | CN¥37.32 Million | ▼ -11.0 pp |
| 2007 | 83.6% | CN¥48.70 Million | CN¥58.24 Million | CN¥9.54 Million | — |